Search Results - "Baltezor, Michael"

Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs by Weir, Scott J, Wood, Robyn, Schorno, Karl, Brinker, Amanda E, Ramamoorthy, Prabhu, Heppert, Kathy, Rajewski, Lian, Tanol, Mehmet, Ham, Tammy, McKenna, Michael J, McCulloch, William, Dalton, Michael, Reed, Gregory A, Jensen, Roy A, Baltezor, Michael J, Anant, Shrikant, Taylor, 3rd, John A

“…Pharmacokinetic studies in rats and dogs were performed to characterize the in vivo performance of a novel prodrug, fosciclopirox. Ciclopirox olamine (CPX-O)…”
Get more information

Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex by Weir, Scott J., Dandawate, Prasad, Standing, David, Bhattacharyya, Sangita, Ramamoorthy, Prabhu, Rangarajan, Parthasarathy, Wood, Robyn, Brinker, Amanda E., Woolbright, Benjamin L., Tanol, Mehmet, Ham, Tammy, McCulloch, William, Dalton, Michael, Reed, Gregory A., Baltezor, Michael J., Jensen, Roy A., Taylor, John A., Anant, Shrikant

“…Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic…”
Get full text

Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly by Wang, Tao, Chen, Ping, Weir, Scott, Baltezor, Michael, Schoenen, Frank J., Chen, Qi

“…Pancreatic cancer is a devastating disease with a dismal prognosis and poor treatment outcomes. Searching for new agents for pancreatic cancer treatment is of…”
Get full text

Novel Compound C150 Inhibits Pancreatic Cancer Cell Epithelial-to-Mesenchymal Transition and Tumor Growth in Mice by Wang, Tao, Chen, Ping, Dong, Ruochen, Weir, Scott, Baltezor, Michael, Schoenen, Frank J, Chen, Qi

“…Pancreatic cancer cell epithelial-to-mesenchymal transition (EMT) is an important contributor to cell invasion and tumor progression. Therefore, targeting EMT…”
Get full text

Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies by diZerega, Gere S., Maulhardt, Holly A., Verco, Shelagh J., Marin, Alyson M., Baltezor, Michael J., Mauro, Samantha A., Iacobucci, Marc A.

“…This review summarizes development of large surface area microparticle paclitaxel (LSAM-PTX) and docetaxel (LSAM-DTX) for local treatment of primary carcinomas…”
Get full text

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies by Williamson, Stephen K., Johnson, Gary A., Maulhardt, Holly A., Moore, Kathleen M., McMeekin, D. S., Schulz, Thomas K., Reed, Gregory A., Roby, Katherine F., Mackay, Christine B., Smith, Holly J., Weir, Scott J., Wick, Jo A., Markman, Maurie, diZerega, Gere S., Baltezor, Michael J., Espinosa, Jahna, Decedue, Charles J.

“…Purpose This multicenter, open-label, dose-escalating, phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary tumor response of a…”
Get full text

Tyr1‑ψ[(Z)CFCH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin by Altman, Ryan A, Sharma, Krishna K, Rajewski, Lian G, Toren, Paul C, Baltezor, Michael J, Pal, Mohan, Karad, Somnath N

“…Opioid peptides are key regulators in cellular and intercellular physiological responses, and could be therapeutically useful for modulating several…”
Get full text

Tyr 1 -ψ[( Z)CF═CH]-Gly 2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin by Altman, Ryan A, Sharma, Krishna K, Rajewski, Lian G, Toren, Paul C, Baltezor, Michael J, Pal, Mohan, Karad, Somnath N

“…Opioid peptides are key regulators in cellular and intercellular physiological responses, and could be therapeutically useful for modulating several…”
Get full text

Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies by Maulhardt, Holly, Verco, Shelagh, Baltezor, Michael, Marin, Alyson, diZerega, Gere

“…This report describes local administration of large surface area microparticle docetaxel (LSAM-DTX: ~ 3.5- to 7.5-µm-sized particles with high relative surface…”
Get full text

A Novel Compound Inhibits Pancreatic Cancer Cell Invasion, Tumor Sphere Formation, and In Vivo Tumor Growth in Mice by Suppressing EMT by Wang, Tao, Dong, Ruochen, Chen, Ping, Baltezor, Michael, Weir, Scott, Chen, Qi

“…Objective Epithelial to Mesenchymal Transition (EMT) has been proposed to contribute importantly to metastasis, cancer stem cell (CSC) generation and drug…”
Get full text

NanoPac inhalation treatment of NSCLC in a nude rat orthotopic lung cancer model by Dizerega, Gere, Johnston, William, Verco, James, Baltezor, Michael Jay, Wolff, Ronald, Kuehl, Philip

“…Abstract only…”
Get full text

EGCG promotes cell growth inhibition and reprograms mesenchymal‐epithelial transition by restoring CCN5/WISP2 in triple negative breast cancer cells in vitro and in vivo by Ghosh, Arnab, Das, Amlan, Banerjee, Snigdha, Baltezor, Michael, Zeng, Liang, Banerjee, Sushanta K.

“…Background and Objective CCN5/WISP‐2, a matricellular secretory protein that is localized in both cytoplasm and nucleus, is mainly expressed in luminal cells…”
Get full text

Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia by Lin, Tara L., Wood, Robyn, Ham, Tammy, Sullivan, Taegen, Dandawate, Prasad, Anant, Shrikant, Santaguida, Marianne T, Toren, Paul, Jensen, Roy A., Taylor, John A., Baltezor, Michael Jay, Dalton, Michael, Meyer, Fred, McBride, John, Umbreit, Jay Nicholas, McCulloch, William, Vanderlaag, Kathryn, Wagner, Joseph, Weir, Scott James, Smith, B. Douglas

“…TPS7078 Background: Fosciclopirox (CPX-POM) is a broad-spectrum anticancer agent being developed through a public-private partnership between CicloMed LLC and…”
Get full text

Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia by Lin, Tara L., Wood, Robyn, Ham, Tammy, Sullivan, Taegen, Bhattacharyya, Sangita, Dandawate, Prasad, Anant, Shrikant, Santaguida, Marianne T, Zhang, Na, Toren, Paul, Jensen, Roy A., Taylor, John A., Baltezor, Michael Jay, Dalton, Michael, McBride, John, Umbreit, Jay Nicholas, McCulloch, William, Vanderlaag, Kathryn, Wagner, Joseph, Weir, Scott James

“…TPS7069 Background: Fosciclopirox (F) is a γ-secretase inhibitor being developed for the treatment of acute myeloid leukemia (AML). Following intravenous (IV)…”
Get full text

Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies by Verco, Shelagh, Maulhardt, Holly, Baltezor, Michael, Williams, Emily, Iacobucci, Marc, Wendt, Alison, Verco, James, Marin, Alyson, Campbell, Sam, Dorman, Paul, diZerega, Gere

“…This report describes local administration of submicron particle paclitaxel (SPP) (NanoPac®: ~ 800-nm-sized particles with high relative surface area with each…”
Get full text

Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis by Ma, Yan, Baltezor, Michael, Rajewski, Lian, Crow, Jennifer, Samuel, Glenson, Staggs, Vincent S., Chastain, Katherine M., Toretsky, Jeffrey A., Weir, Scott J., Godwin, Andrew K.

“…Ewing sarcoma (ES) are aggressive pediatric bone and soft tissue tumors driven by EWS-ETS fusion oncogenes, most commonly EWS-FLI1 . Treatment of ES patients…”
Get full text

Abstract 6405: Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting Notch signaling by Weir, Scott James, Dandawate, Prasad, Ramamoorthy, Prabhu, Ranjarajan, Parthasarathy, Wood, Robyn, Brinker, Amanda, Woolbright, Benjamin, Tanol, Mehmet, Ham, Tammy, McCulloch, William, Dalton, Michael, Baltezor, Michael J., Jensen, Roy A., Taylor, John A., Anant, Shrikant

“…Ciclopirox (CPX) is a FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in solid and hematologic malignancies. It's…”
Get full text

Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients by Taylor, John Arthur, Wood, Robyn, Ham, Tammy, Casey, Crista, Dandawate, Prasad, Reed, Greg, Woolbright, Benjamin L., Baltezor, Michael Jay, Jensen, Roy A., Dalton, Michael, Zhukova-Harrill, Valentina, McCulloch, William, Anant, Shrikant, Weir, Scott James

“…Abstract only TPS604 Background: Fosciclopirox (Ciclopirox Prodrug, CPX-POM) is being developed for the treatment of non-muscle invasive and muscle invasive…”
Get full text

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac ® ) in a Rodent Model by Verco, James, Johnston, William, Baltezor, Michael, Kuehl, Philip J, Gigliotti, Andrew, Belinsky, Steven A, Lopez, Anita, Wolff, Ronald, Hylle, Lauren, diZerega, Gere

“…Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The…”
Get more information

Abstract 1895: Ciclopirox prodrug for the prevention and therapy of non-muscle invasive bladder cancer by Rangarajan, Parthasarathy, Ramalingam, Satish, Subramaniam, Dharmalingam, Baltezor, Michael J., Wood, Robyn, Anant, Shrikant, Weir, Scott

“…Objective: Ciclopirox prodrug for the prevention of Non-Muscle Invasive Bladder Cancer (NMIBC) represents a potential breakthrough in the management of…”
Get full text